Top

Published in:

01-07-2005 | Original Article

Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study

Authors: Adrian G. Ruetsche, Renato Kneubuehl, Martin H. Birkhaeuser, Kurt Lippuner

Published in: Osteoporosis International | Issue 7/2005

Abstract

The aim of this study was to explore the effect of long-term cross-sex hormonal treatment on cortical and trabecular bone mineral density and main biochemical parameters of bone metabolism in transsexuals. Twenty-four male-to-female (M-F) transsexuals and 15 female-to-male (F-M) transsexuals treated with either an antiandrogen in combination with an estrogen or parenteral testosterone were included in this cross-sectional study. BMD was measured by DXA at distal tibial diaphysis (TDIA) and epiphysis (TEPI), lumbar spine (LS), total hip (HIP) and subregions, and whole body (WB) and Z-scores determined for both the genetic and the phenotypic gender. Biochemical parameters of bone turnover, insulin-like growth factor-1 (IGF-1) and sex hormone levels were measured in all patients. M-F transsexuals were significantly older, taller and heavier than F-M transsexuals. They were treated by cross-sex hormones during a median of 12.5 years before inclusion. As compared with female age-matched controls, they showed a significantly higher median Z-score at TDIA and WB (1.7±1.0 and 1.8±1.1, P<0.01) only. Based on the WHO definition, five (who did not comply with cross-sex hormone therapy) had osteoporosis. F-M transsexuals were treated by cross-sex hormones during a median of 7.6 years. They had significantly higher median Z-scores at TEPI, TDIA and WB compared with female age-matched controls (+0.9±0.2 SD, +1.0±0.4 SD and +1.4±0.3 SD, respectively, P<0.0001 for all) and reached normal male levels except at TEPI. They had significantly higher testosterone and IGF-1 levels (p<0.001) than M-F transsexuals. We conclude that in M-F transsexuals, BMD is preserved over a median of 12.5 years under antiandrogen and estrogen combination therapy, while in F-M transsexuals BMD is preserved or, at sites rich in cortical bone, is increased to normal male levels under a median of 7.6 years of androgen treatment in this cross sectional study. IGF-1 could play a role in the mediation of the effect of androgens on bone in F-M transsexuals.

Holmes SJ, Shalet SM (1996) Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Horm Res 45:86–93PubMed

Delmas PD (1997) Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos Int 7 Suppl 1:S3–7

Saggese G, Bertelloni S, Baroncelli GI (1997) Sex steroids and the acquisition of bone mass. Horm Res 48 Suppl 5:65–71

(1997) Consensus development statement on osteoporosis: who are candidates for prevention and treatment of osteoporosis. Osteoporos Int 7:1–6

Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763–773PubMed

Gibaldi M (1997) Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? J Clin Pharmacol 37:1087–1099PubMed

Rozenberg S, Vandromme J, Kroll M, Pastijn A, Degueldre M (1994) Osteoporosis prevention with sex hormone replacement therapy. Int J Fertil Menopausal Stud 39:262–271PubMed

Swerdloff RS, Wang C (1993) Androgens and aging in men. Exp Gerontol 28:435–446CrossRefPubMed

Winters SJ (1999) Current status of testosterone replacement therapy in men. Arch Fam Med 8:257–263CrossRefPubMed

10.

Hansen KA, Tho SP (1998) Androgens and bone health. Semin Reprod Endocrinol 16:129–134PubMed

11.

Goh HH, Ratnam SS (1997) Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals. Maturitas 26:45–52CrossRefPubMed

12.

Lips P, Asscheman H, Uitewaal P, Netelenbos JC, Gooren L (1989) The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. J Bone Miner Res 4:657–662PubMed

13.

Lips P, van Kesteren PJ, Asscheman H, Gooren LJ (1996) The effect of androgen treatment on bone metabolism in female-to-male transsexuals. J Bone Miner Res 11:1769–1773PubMed

14.

van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H, Megens J, Gooren L (1996) The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. J Clin Endocrinol Metab 81:2227–2232CrossRefPubMed

15.

van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J (1998) Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 48:347–354

16.

van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ (1997) Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47:337–342

17.

Colvard D, Spelsberg T, Eriksen E, Keeting P, Riggs BL (1989) Evidence of steroid receptors in human osteoblast-like cells. Connect Tissue Res 20:33–40PubMed

18.

Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389–425CrossRefPubMed

19.

Wiren KM, Chapman Evans A, Zhang XW (2002) Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J Endocrinol 175:683–694PubMed

20.

Schlatterer K, Yassouridis A, von Werder K, Poland D, Kemper J, Stalla GK (1998) A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Arch Sex Behav 27:475–492CrossRefPubMed

21.

Casez JP, Troendle A, Lippuner K, Jaeger P (1994) Bone mineral density at distal tibia using dual-energy X-ray absorptiometry in normal women and in patients with vertebral osteoporosis or primary hyperparathyroidism. J Bone Miner Res 9:1851–1857PubMed

22.

Duncan EL, Cardon LR, Sinsheimer JS, Wass JA, Brown MA (2003) Site and gender specificity of inheritance of bone mineral density. J Bone Miner Res 18:1531–1538PubMed

23.

Rubin K, Schirduan V, Gendreau P, Sarfarazi M, Mendola R, Dalsky G (1993) Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. J Pediatr 123:863–870PubMed

24.

Bonjour JP, Theintz G, Law F, Slosman D, Rizzoli R (1994) Peak bone mass. Osteoporos Int 4 Suppl 1:7–13

25.

Martin B (1993) Aging and strength of bone as a structural material. Calcif Tissue Int 53 Suppl 1:S34–39; discussion S39–40

26.

Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841–1850CrossRefPubMed

27.

Seeman E (2003) The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin N Am 32:25–38

28.

van der Meulen MC, Ashford MW Jr, Kiratli BJ, Bachrach LK, Carter DR (1996) Determinants of femoral geometry and structure during adolescent growth. J Orthop Res 14:22–29PubMed

29.

Ruff CB, Hayes WC (1988) Sex differences in age-related remodeling of the femur and tibia. J Orthop Res 6:886–896PubMed

30.

Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC (1995) Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95:2886–2895PubMed

31.

Orwoll ES, Bauer DC, Vogt TM, Fox KM (1996) Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Int Med 124:187–196PubMed

32.

Mauras N, Blizzard RM, Link K, Johnson ML, Rogol AD, Veldhuis JD (1987) Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J Clin Endocrinol Metab 64:596–601PubMed

33.

Gillberg P, Olofsson H, Mallmin H, Blum WF, Ljunghall S, Nilsson AG (2002) Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men. Calcif Tissue Int 70:22–29CrossRefPubMed

34.

Vestergaard P, Hermann AP, Orskov H, Mosekilde L (1999) Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J Clin Endocrinol Metab 84:2286–2290CrossRefPubMed

35.

Collins D, Woods A, Herd R, Blake G, Fogelman I, Wheeler M, Swaminathan R (1998) Insulin-like growth factor-I and bone mineral density. Bone 23:13–16CrossRefPubMed

36.

Karasik D, Rosen CJ, Hannan MT, Broe KE, Dawson-Hughes B, Gagnon DR, Wilson PW, Visser M, Langlois JA, Mohan S, Kiel DP (2002) Insulin-like growth factor binding proteins 4 and 5 and bone mineral density in elderly men and women. Calcif Tissue Int 71:323–328CrossRefPubMed

37.

Vered I, Kaiserman I, Sela BA, Sack J (1997) Cross genotype sex hormone treatment in two cases of hypogonadal osteoporosis. J Clin Endocrinol Metab 82:576–578CrossRefPubMed

38.

Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS (2002) Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab 87:2798–2808CrossRefPubMed

Title: Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study
Authors: Adrian G. Ruetsche
Renato Kneubuehl
Martin H. Birkhaeuser
Kurt Lippuner
Publication date: 01-07-2005
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 7/2005
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-004-1754-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2005

Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry

Image resolution and magnification using a cone beam densitometer: optimizing data acquisition for hip morphometric analysis

An osteoporosis screening tool for Chinese men

A meta-analysis of milk intake and fracture risk: low utility for case finding

Physical training and hormone replacement therapy reduce the decrease in bone mineral density in perimenopausal women: a pilot study

Identification of vertebral fractures: An update